Literature DB >> 11396096

Pathogenesis of rheumatoid arthritis. Role of B lymphocytes.

Z Zhang1, S L Bridges.   

Abstract

Despite many years of investigation, there remain many unanswered fundamental questions on the role of B cells in RA. Why is RF found in the sera of 80% of patients with RA and often in other chronic inflammatory diseases? What signals lead B lymphocytes to migrate into the subsynovial lining of joints? Does receptor revision in synovium play a role in the generation of autoantibodies in RA? What is the relative contribution of B-cell inhibition on the salutary effect of medications for RA? Can targeting autoreactive B cells, in conjunction with other therapies, provide therapeutic benefit in RA? We are hopeful that through continued basic, clinical, and translational research, these questions can be answered.

Entities:  

Mesh:

Year:  2001        PMID: 11396096     DOI: 10.1016/s0889-857x(05)70205-2

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  13 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Antibodies to citrullinated proteins: pathogenic and diagnostic significance.

Authors:  V Michael Holers
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

Review 3.  Genetic influences on rheumatoid arthritis in African Americans.

Authors:  Laura B Hughes; Larry W Moreland; S Louis Bridges
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action.

Authors:  Xiaolei Tang; David E Yocum; David Dejonghe; Kathryn Nordensson; Douglas F Lake; John Richard
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

5.  Occupations and exposures in the work environment as determinants for rheumatoid arthritis.

Authors:  A Reckner Olsson; T Skogh; O Axelson; G Wingren
Journal:  Occup Environ Med       Date:  2004-03       Impact factor: 4.402

6.  (99m)Tc-labeled rituximab for imaging B lymphocyte infiltration in inflammatory autoimmune disease patients.

Authors:  G Malviya; K L Anzola; E Podestà; B Laganà; C Del Mastro; R A Dierckx; F Scopinaro; A Signore
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

Review 7.  The potential utility of B cell-directed biologic therapy in autoimmune diseases.

Authors:  D G Arkfeld
Journal:  Rheumatol Int       Date:  2007-10-24       Impact factor: 2.631

8.  B cells as a therapeutic target in autoimmune disease.

Authors:  Jörg J Goronzy; Cornelia M Weyand
Journal:  Arthritis Res Ther       Date:  2003-03-19       Impact factor: 5.156

Review 9.  Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.

Authors:  John D Hainsworth
Journal:  Arthritis Res Ther       Date:  2003-12-02       Impact factor: 5.156

Review 10.  Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology.

Authors:  Anatoliy Gladkevich; S Adriaan Nelemans; Henk F Kauffman; Jakob Korf
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.